glp-1 insulin GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Targeting GLP-1, GIP & GCG

Nanomedicines, owing to their nanoscale size and multi-functional design, facilitate precise tumor targeting, controlled drug release and enhanced bioavailability, thereby offering innovative solutions to modulate tumor lactate metabolism and amplify antitumor efficacy (150)

All patients were studied in a supine position, measurements of the gastric antrum were always taken from the outer profile of the wall because the lumen of the antrum is usually very narrow, the cross section of the gastric antrum was measured, corresponding to the antral diameter, (forms an elliptical shape)

The decision to use GLP-1 receptor agonists should be based on their licensed indications (diabetes or obesity management) rather than cholesterol lowering alone, with lipid improvements considered a beneficial additional effect within a comprehensive cardiovascular risk reduction strategy

J Pharmacol Exp Ther (2002) 300(3):95866

: 32 ( 5 )